Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | HTR1F | P30939 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 4/20 | 0.44 |
| ▸ | NOS2 | P35228 | 3/20 | 0.44 |
| ▸ | NOS1 | P29475 | 3/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29645408 | 1.00 | HTR1A (0.48) | HTR1ADRD2DRD4HTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL31655491 | 0.98 | HTR1A (0.47) | HTR1ADRD2DRD4HTR1DHTR1B | |
| SCHEMBL29900984 | 0.83 | ASIC3 (0.43) | HTR1ADRD2DRD4NOS3NOS2 | |
| SCHEMBL3925163 | 0.83 | ASIC3 (0.43) | HTR1ADRD2DRD4NOS3NOS2 | |
| SCHEMBL23089594 | 0.81 | DRD2 (0.45) | HTR1ADRD2DRD4NOS3NOS2 | |
| SCHEMBL29814708 | 0.81 | DRD2 (0.45) | HTR1ADRD2DRD4NOS3NOS2 | |
| SCHEMBL17888476 | 0.81 | DRD2 (0.53) | HTR1ADRD2DRD4MAP4K4HTR3E | |
| SCHEMBL15091015 | 0.80 | HTR1A (0.41) | HTR1ADRD2DRD4NOS3NOS2 | |
| SCHEMBL25121130 | 0.79 | USP7 (0.41) | HTR1ADRD2DRD4HTR1DHTR1B | |
| SCHEMBL23865578 | 0.79 | HTR1A (0.48) | HTR1ADRD2DRD4PARP1USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164952-A | Preparation method of masmipide | 山东新时代药业有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118164952-A | Preparation method of masmipide | 山东新时代药业有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-116925037-A | Preparation method of 2-amino-6- (1-methylpiperidine-4-ylcarbonyl) pyridine | 山东新时代药业有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-115594665-A | Novel preparation method of rasemiptan | 北京万全德众医药生物技术有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-115477635-A | Preparation method of rasemiptan | 山东新时代药业有限公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-114685439-A | Preparation method of rasemiptan | 鲁南制药集团股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-10669256-B2 | Crystalline forms of lasmiditan, preparation methods, pharmaceutical compositions and uses thereof | HANGZHOU SOLIPHARMA CO., LTD. (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190233393-A1 | CRYSTALLINE FORM OF RECEPTOR AGONIST, AND MANUFACTURING METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | SOLIPHARMA LLC (CN) | 2019-08-01 | — | — | US | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233393-A1 | CRYSTALLINE FORM OF RECEPTOR AGONIST, AND MANUFACTURING METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | HTR1F, HTR1D, HTR1A | HTR1A 3/4885DRD2 361/4885DRD4 840/4885 |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | HTR1A 4710/4885DRD2 4789/4885DRD4 4383/4885 |
| US-10669256-B2 | Crystalline forms of lasmiditan, preparation methods, pharmaceutical compositions and uses thereof | HTR1F, HTR1D, HTR1A | HTR1A 3/4885DRD2 468/4885DRD4 1082/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | HTR1A 4710/4885DRD2 4789/4885DRD4 4383/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | HTR1A 4710/4885DRD2 4789/4885DRD4 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.